Target intelligence / Profile preview

Immediate-early 1 protein (IE1)

Target
IE1
Molecular classification
Other (viral regulatory protein), Transcription factor (functionally, but not a cellular transcription factor), Viral effector protein
01

Overview

The **immediate-early 1 protein (IE1)** is a multifunctional viral regulatory protein encoded by cytomegaloviruses, a subgroup of betaherpesviruses, including human cytomegalovirus (HCMV)[1][2][3][4]. **IE1 is abundantly produced during the earliest phase of viral infection, preceding the expression of early and late genes.** It acts primarily in the host cell nucleus, where it targets host chromatin by binding directly to core histones, modifies chromatin structure, and regulates both viral and cellular gene expression—acting as both an activator and repressor of transcription[3][4]. IE1 plays a well-defined role in viral immune evasion by directly antagonizing the cellular restriction factor promyelocytic leukemia protein (PML) and dismantling PML nuclear bodies, thus overcoming intrinsic antiviral defenses[2]. Moreover, IE1 interacts with and redirects host cell signaling: it disrupts IL6-mediated STAT3 signaling to activate STAT1-dependent transcription, reshaping cytokine responses to benefit viral pathogenesis[4]. Structurally, IE1 proteins form a unique, highly conserved tertiary and quaternary configuration with species-specific adaptations, facilitating efficient PML targeting within their natural host[2][3]. Although IE1 is essential for viral replication and immune modulation, **it is not considered a therapeutic target in the conventional sense (such as a receptor, enzyme, or transporter), and no approved drugs act directly on IE1.** IE1 protein or antibodies against it may serve as evidence of active or latent cytomegalovirus infection but are not currently used as clinical biomarkers for treatment selection or monitoring[3]. **Note:** "Immediate-early 1 protein" is specific to cytomegaloviruses and is not a human gene product. This makes it distinct from conventional drug targets, most of which are endogenous human proteins. There is no direct evidence that IE1 is the target of any approved antiviral agents, and no small-molecule inhibitors for clinical use are currently known.

Other names
IE1Major immediate-early 1 proteinImmediate early protein 1UL123 gene product (in human cytomegalovirus)IE72IE1-72kDa
02

Biological functions

Regulation of viral and host transcriptionAntagonism of host restriction factors (notably PML nuclear bodies)Immune evasionChromatin binding and remodelingModulation of host cell signaling pathways (notably STAT pathways)Reprogramming of host antiviral responses
03

Disease associations

Infection (critical for cytomegalovirus infection and replication)Other (not directly implicated in non-infectious diseases)
04

Biomarkers

IE1 itself is used as a biomarker for cytomegalovirus infection but not as a biomarker for patient selection or efficacy monitoring of treatment

Beyond the preview

Go deeper on Immediate-early 1 protein (IE1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immediate-early 1 protein (IE1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call